All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
Now you can personalise
your MDS Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for youFind out more
Bookmark this article
“How I treat” based on the new/updated classification systems
Fenaux highlights the differences between the 5th edition of the World Health Organization Classification of Hematolymphoid Tumors and the International Consensus Classification of Myeloid Neoplasms and Acute Leukemia, outlining the consequences of these differences in the management of MDS. He also discusses the Molecular International Prognostic Scoring System and the impact of a patient's mutational profile on treatment decision-making. Fenaux continues by describing the updates in the International Working Group 2023 response criteria for higher-risk (MDS). To conclude, the committee discusses factors that influence transplant decision-making and the use of azacitidine and venetoclax as a bridge to transplant.
Quality of life assessment and transfusion-free survival
During the MDS Hub Steering Committee meeting held on May 11, 2023, Theo de Witte chaired a discussion on quality of life assessment and transfusion-free survival in patients with MDS, with...
Visual abstract | Key updates to the classification of MDS in the 5th WHO Classification of Haematolymphoid Tumours
In this visual abstract, the MDS Hub summarizes the key updates to the classification of MDS from the 5th edition of the WHO...
Subscribe to get the best content related to MDS delivered to your inbox